Novo Nordisk A/S (NONOF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Bagsvaerd, Denmark. Der aktuelle CEO ist Maziar Mike Doustdar.
NONOF hat IPO-Datum 2010-05-07, 77,406 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $172.47B.
Novo Nordisk A/S is a global healthcare company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company operates through two primary segments: Diabetes and Obesity Care, which includes insulins, GLP-1 therapies, oral antidiabetic products, and obesity treatments; and Biopharmaceuticals, which focuses on haemophilia, growth disorders, and hormone replacement therapy. Founded in 1923 and headquartered in Bagsvaerd, Denmark, Novo Nordisk maintains strategic collaborations with industry partners including Gilead Sciences and Lumen Bioscience to advance its pipeline in cardiometabolic disease treatments.
